Related Experiment Video
Updated: Feb 23, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Bevacizumab-induced hypertension: Clinical presentation and molecular understanding
1Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, United States.
Abstract:
Bevacizumab is a vascular endothelial growth factor-A-specific angiogenesis inhibitor indicated as an adjunct to chemotherapy for the treatment of several types of cancer. Hypertension is commonly observed during bevacizumab treatment, and high-grade toxicity can limit therapy and lead to other cardiovascular complications. The factors that contribute to interindividual variability in blood pressure response to bevacizumab treatment are not well understood. In this review, we outline research efforts to understand the mechanisms and pathophysiology of hypertension resulting from bevacizumab treatment. Moreover, we highlight current knowledge of the pharmacogenetics of bevacizumab-induced hypertension, which may be used to develop strategies to prevent or minimize this toxicity.
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension II: Pathophysiology
Hypertension I: Introduction
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Hypertension and Regulation of Blood Pressure
Hypertension V: Nursing Management

